PRINCIPIA ANNOUNCES POSITIVE PRELIMINARY DATA OF PRN1008 FOR IMMUNE THROMBOCYTOPENIA IN ONGOING PHASE 1/2 TRIAL Preliminary results from trial have been accepted as an oral presentation at upcoming American Society of Hematology Annual Meeting SOUTH SAN FRANCISCO,...
PRINCIPIA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) — Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated...
PRINCIPIA ANNOUNCES POSITIVE PRELIMINARY DATA OF PRN1008 FROM ITS ONGOING PHASE 2 PART B TRIAL IN PEMPHIGUS Consistent efficacy and safety profile for pemphigus patients observed Confirms 400mg twice daily dose in Phase 3 trial Principia to host investor conference...
Neurana Pharmaceuticals Announces Positive Topline Results from Phase 2 STAR Study of Tolperisone in Acute Muscle Spasms of the Back Tolperisone shown to be effective in treating pain due to acute back muscle spasm • Tolperisone was well-tolerated and did not increase...
Deciphera Pharmaceuticals Announces Late-Breaking Oral Presentation at the ESMO 2019 Congress Demonstrating Positive Results from INVICTUS Pivotal Phase 3 Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors WALTHAM, Mass.–(BUSINESS...
Recent Comments